Circio Holding ASA completes directed issue of NOK 3.6 million

06 Feb 2026 11:48 CET

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY,
IN OR INTO THE UNITED STATES OF AMERICA, THE UNITED KINGDOM, AUSTRALIA,
CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT
CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 6 February 2026 -- Circio Holding ASA (OSE: CRNA), a
biotechnology company developing novel circular RNA expression technology for
gene and cell therapy, today announces that it has successfully completed a
directed share issue for NOK 3.6 million at a subscription price of NOK 1.00
per share (the "Directed Issue"). The Directed Issue was carried out pursuant
to the board authorization to increase the share capital, as resolved by the
extraordinary general meeting held on 12 January 2026.

Following the oversubscribed rights issue (link to press release
(https://www.circio.com/en/circio-holding-asa-announces-substantially-oversubscr
ibed-preliminary-result-of-the-rights-issue/)),
certain existing shareholders and other investors contacted the company
offering additional equity at the same subscription price per share, without
attached warrants. Circio's board of directors (the "Board") judged that this
additional capital will further improve the financial position and strengthen
the shareholder base, and therefore resolved to proceed with the Directed
Issue for NOK 3.6 million.

The Directed Issue is carried out in addition to the recently completed rights
issue of NOK 50 million and parallel private placement of approximately NOK 15
million. This brings the total combined gross proceeds from recent
transactions to approximately NOK 68.6 million.

The Directed Issue represents a deviation from the shareholders' pre-emptive
right to subscribe for new shares in the company. The Board has carefully
considered the structure of the equity raise in light of the equal treatment
obligations under the Norwegian Public Limited Liability Companies Act and the
Norwegian Securities Trading Act, and the Board is of the opinion that it is
in compliance with these principles. The Board is of the view that it will be
in the common interest of Circio and its shareholders to raise equity through
the Directed Issue, in particular because the Directed Issue enables the
company to raise equity materially faster and at significantly lower cost
compared to another rights issue, the dilution to existing shareholders is
minimal, and the additional equity will extend its financial runway.

The Directed Issue does not involve issuance of any warrants (Nw.:
frittstående tegningsretter), and no manager fee is applicable. Further, the
subscription price of NOK 1.00 is the same as in the Rights Issue and the
Private Placement, and represents only a small discount to the current trading
prices of Circio's shares, and with the total size, resulting in minimal
dilution for existing shareholders.

The Board has therefore resolved to increase the Company's share capital by
NOK 2,160,000 through the issuance of 3,600,000 new shares through the
Directed Issue, each with a nominal value of NOK 0.60 and a subscription price
of NOK 1.00 per share.

The shares issued in the Directed Issue are expected to be tradable on
Euronext Oslo Børs on or about 11 February 2026.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation (MAR) and is subject to the disclosure requirements
pursuant to MAR article 17 and section 5-12 of the Norwegian Securities
Trading Act. The information was submitted for publication at 2026-02-06 11:48
CET.

This stock exchange announcement was published by Mats Hermansen, VP Finance,
on behalf of the Company, at the time and date stated above in this
announcement.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683 34 3811
Email: lubor.gaal@circio.com

About Circio
Building circular RNA expression systems for enhanced gene and cell therapies

Circio Holding ASA is a biotechnology company developing novel circular RNA
expression technology for gene and cell therapy.

Circio has established a unique circular RNA (circRNA) vector expression
technology for next generation RNA, DNA and viral therapeutics. The
proprietary circVec platform is based on a modular genetic construct designed
for efficient biogenesis of multifunctional circRNA inside target cells. The
circVec platform has applications in multiple therapeutic settings, including
genetic medicine, cell therapy and chronic disease. It has demonstrated
75-fold increased RNA half-life and up to 40-fold enhanced protein expression
vs. conventional mRNA-based viral and non-viral vector systems, with the
potential to become a new gold-standard gene expression technology. The
circVec R&D activities are being conducted by the wholly owned subsidiary
Circio AB in Stockholm, Sweden.

In parallel, Circio is continuing to develop its legacy immuno-oncology
program, TG01, through cost-efficient external academic and industry
collaborations. TG01 targets RAS-mutated cancers and is being tested in two
clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine
adjuvanted by STIMULON QS-21 licensed from Agenus Inc.

More information:
Access the news on Oslo Bors NewsWeb site